Alicia Haydo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alicia Haydo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Donat Kögel
Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany
3 shared publications - Alisha Crider
Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany
2 shared publications - Benedikt Linder
Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany
2 shared publications - Francesco Pampaloni
Buchmann Inst. for Molecular Life Sciences, Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany
2 shared publications - Franz Rödel
Department of Radiation Oncology, University Hospital, Johann Wolfgang Goethe University, 60590 Frankfurt, Germany
2 shared publications - Irmgard Tegeder
Institute of Clinical Pharmacology, Faculty of Medicine, Goethe-University, Frankfurt, Germany
2 shared publications
Latest Publications
- Open Access
- 11 September 2025
- Published by University Library J. C. Senckenberg
Novel strategies for the targeted elimination of glioblastoma- and glioblastoma stem-like cells
Glioblastoma (GBM), the most aggressive and common primary brain tumor, presents significant therapeutic challenges due to its inherent resistance to conventional treatments, such as radiotherapy and chemotherapy, and its diffuse infiltration into brain tissue, which precludes complete surgical resection. A profound understanding of the processes underlying GBM cell migration and invasion within a physiological microenvironment is crucial for developing more effective therapeutic strategies. In this thesis, an innovative methodology that combines adult organotypic brain tissue slice culture (OTC) and light-sheet fluorescence microscopy (LSFM) of cleared tissues, termed OTCxLSFM was developed. This combined technique enables high-resolution, three-dimensional visualization of GBM tissue infiltration at a single-cell level, providing detailed morphological insights into tumor cells. Using the OTCxLSFM methodology, it was demonstrated that GBM tissue infiltration can be effectively inhibited through various interventions. Specifically, genetic depletion of the tetraspanin transmembrane receptor CD9 or the signal transducer and activator of transcription 3 (STAT3), or treatments with arsenic trioxide (ATO) or the JAK2/STAT3 inhibitor WP1066, significantly reduced tumor cell infiltration. These findings highlight the potential of targeting specific molecular pathways to interfere GBM progression. Furthermore, preliminary research has identified BRCA1-associated ATM -activator 1 (BRAT1) as a crucial factor in the pathogenesis of GBM. BRAT1 drives key aspects of GBM characteristics, including the DNA damage response (DDR) and tumor cell migration. For this purpose, a stable depletion of BRAT1 was established in adherent GBM cells. To analyze the subpopulation within GBM tumors, stem cell-like (GSC) GBM tumor spheres, which express typical stem cell markers, were additionally used. The stable BRAT1 depletion in both cell models led to impaired DNA repair of DNA double-strand breaks (DSB) and increased radiation sensitivity in vitro. Furthermore, the BRAT1 depletion significantly inhibited tumor growth and invasion, which were corroborated by both in vitro and in vivo studies. In orthotopic mouse models, transplantation of BRAT1-depleted GSCs resulted in significantly extended overall survival. Preliminary proteomic analysis revealed that a substantial proportion of downregulated proteins in BRAT1-depleted cells are associated with cell migration and invasion, underscoring BRAT1's role in these processes. Importantly, the OTCxLSFM technique was successfully applied to study the effects of BRAT1 inhibition in GBM, by treating GSCs with the BRAT1 inhibitor Curcusone D (CurD), which significantly impeded cell migration and invasion. The migration and invasion of GBM cells and GSCs was also inhibited in in vitro assays using CurD. In addition, CurD particularly when combined with irradiation, led to a synergistic inhibition of tumor growth and infiltration in an ex vivo model using GSCs, further validating the potential of BRAT1 as a new therapeutic target. In conclusion, the OTCxLSFM methodology provides a powerful tool for investigating the complex mechanisms of GBM infiltration and identifying potential therapeutic targets. These findings establish BRAT1 as a promising target for GBM treatment and highlight CurD as a candidate for targeted therapy development. This approach holds significant promise for improving therapeutic outcomes in patients with this aggressive and challenging disease.
- 11 September 2025
- Published by University Library J. C. Senckenberg
Open AccessNovel strategies for the targeted elimination of glioblastoma- and glioblastoma stem-like cells
Glioblastoma (GBM), the most aggressive and common primary brain tumor, presents significant therapeutic challenges due to its inherent resistance to conventional treatments, such as radiotherapy and chemotherapy, and its diffuse infiltration into brain tissue, which precludes complete surgical resection. A profound understanding of the processes underlying GBM cell migration and invasion within a physiological microenvironment is crucial for developing more effective therapeutic strategies. In this thesis, an innovative methodology that combines adult organotypic brain tissue slice culture (OTC) and light-sheet fluorescence microscopy (LSFM) of cleared tissues, termed OTCxLSFM was developed. This combined technique enables high-resolution, three-dimensional visualization of GBM tissue infiltration at a single-cell level, providing detailed morphological insights into tumor cells. Using the OTCxLSFM methodology, it was demonstrated that GBM tissue infiltration can be effectively inhibited through various interventions. Specifically, genetic depletion of the tetraspanin transmembrane receptor CD9 or the signal transducer and activator of transcription 3 (STAT3), or treatments with arsenic trioxide (ATO) or the JAK2/STAT3 inhibitor WP1066, significantly reduced tumor cell infiltration. These findings highlight the potential of targeting specific molecular pathways to interfere GBM progression. Furthermore, preliminary research has identified BRCA1-associated ATM -activator 1 (BRAT1) as a crucial factor in the pathogenesis of GBM. BRAT1 drives key aspects of GBM characteristics, including the DNA damage response (DDR) and tumor cell migration. For this purpose, a stable depletion of BRAT1 was established in adherent GBM cells. To analyze the subpopulation within GBM tumors, stem cell-like (GSC) GBM tumor spheres, which express typical stem cell markers, were additionally used. The stable BRAT1 depletion in both cell models led to impaired DNA repair of DNA double-strand breaks (DSB) and increased radiation sensitivity in vitro. Furthermore, the BRAT1 depletion significantly inhibited tumor growth and invasion, which were corroborated by both in vitro and in vivo studies. In orthotopic mouse models, transplantation of BRAT1-depleted GSCs resulted in significantly extended overall survival. Preliminary proteomic analysis revealed that a substantial proportion of downregulated proteins in BRAT1-depleted cells are associated with cell migration and invasion, underscoring BRAT1's role in these processes. Importantly, the OTCxLSFM technique was successfully applied to study the effects of BRAT1 inhibition in GBM, by treating GSCs with the BRAT1 inhibitor Curcusone D (CurD), which significantly impeded cell migration and invasion. The migration and invasion of GBM cells and GSCs was also inhibited in in vitro assays using CurD. In addition, CurD particularly when combined with irradiation, led to a synergistic inhibition of tumor growth and infiltration in an ex vivo model using GSCs, further validating the potential of BRAT1 as a new therapeutic target. In conclusion, the OTCxLSFM methodology provides a powerful tool for investigating the complex mechanisms of GBM infiltration and identifying potential therapeutic targets. These findings establish BRAT1 as a promising target for GBM treatment and highlight CurD as a candidate for targeted therapy development. This approach holds significant promise for improving therapeutic outcomes in patients with this aggressive and challenging disease.
- Open Access
- 21 January 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-23
BRAT1 - a new therapeutic target for glioblastoma
Glioblastoma (GBM), the most malignant primary brain tumor in adults, has poor prognosis irrespective of therapeutic advances due to its radio-resistance and infiltrative growth into brain tissue. The present study assessed functions and putative druggability of BRCA1-associated ATM activator 1 (BRAT1) as a crucial factor driving key aspects of GBM, including enhanced DNA damage response and tumor migration. By a stable depletion of BRAT1 in GBM and glioma stem-like (GSC) cell lines, we observed a delay in DNA double-strand break repair and increased sensitivity to radiation treatment, corroborated by in vitro and in vivo studies demonstrating impaired tumor growth and invasion. Proteomic and phosphoproteomic analyses further emphasize the role of BRAT1’s cell migration and invasion capacity, with a notable proportion of downregulated proteins associated with these processes. In line with the genetic manipulation, we found that treatment with the BRAT1 inhibitor Curcusone D (CurD) significantly reduced GSC migration and invasion in an ex vivo slice culture model, particularly when combined with irradiation, resulting in a synergistic inhibition of tumor growth and infiltration. Our results reveal that BRAT1 contributes to GBM growth and invasion and suggest that therapeutic inhibition of BRAT1 with CurD or similar compounds might constitute a novel approach for anti-GBM directed treatments.
- 21 January 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-23
Open AccessBRAT1 - a new therapeutic target for glioblastoma
Glioblastoma (GBM), the most malignant primary brain tumor in adults, has poor prognosis irrespective of therapeutic advances due to its radio-resistance and infiltrative growth into brain tissue. The present study assessed functions and putative druggability of BRCA1-associated ATM activator 1 (BRAT1) as a crucial factor driving key aspects of GBM, including enhanced DNA damage response and tumor migration. By a stable depletion of BRAT1 in GBM and glioma stem-like (GSC) cell lines, we observed a delay in DNA double-strand break repair and increased sensitivity to radiation treatment, corroborated by in vitro and in vivo studies demonstrating impaired tumor growth and invasion. Proteomic and phosphoproteomic analyses further emphasize the role of BRAT1’s cell migration and invasion capacity, with a notable proportion of downregulated proteins associated with these processes. In line with the genetic manipulation, we found that treatment with the BRAT1 inhibitor Curcusone D (CurD) significantly reduced GSC migration and invasion in an ex vivo slice culture model, particularly when combined with irradiation, resulting in a synergistic inhibition of tumor growth and infiltration. Our results reveal that BRAT1 contributes to GBM growth and invasion and suggest that therapeutic inhibition of BRAT1 with CurD or similar compounds might constitute a novel approach for anti-GBM directed treatments.
- Open Access
BRAT1 - a new therapeutic target for glioblastoma
Glioblastoma (GBM), the most malignant primary brain tumor in adults, has poor prognosis irrespective of therapeutic advances due to its radio-resistance and infiltrative growth into brain tissue. The present study assessed functions and putative druggability of protein breast cancer type 1 susceptibility protein (BRCA1)-associated Ataxia telangiectasia mutated (ATM)-activator 1 (BRAT1) as a crucial factor driving key aspects of GBM, including enhanced DNA damage response and tumor migration. By a stable depletion of BRAT1 in GBM and glioma stem-like (GSC) cell lines, we observed a delay in DNA double-strand break repair and increased sensitivity to radiation treatment, corroborated by in vitro and in vivo studies demonstrating impaired tumor growth and invasion. Proteomic analyses further emphasize the role of BRAT1’s cell migration and invasion capacity, with a notable proportion of downregulated proteins associated with these processes. In line with the genetic manipulation, we found that treatment with the BRAT1 inhibitor Curcusone D (CurD) significantly reduced GSC migration and invasion in an ex vivo slice culture model, particularly when combined with irradiation, resulting a synergistic inhibition of tumor growth and infiltration. Our results reveal that BRAT1 contributes to GBM growth and invasion and suggest that therapeutic inhibition of BRAT1 with CurD or similar compounds might constitute a novel approach for anti-GBM directed treatments.
Open AccessBRAT1 - a new therapeutic target for glioblastoma
Glioblastoma (GBM), the most malignant primary brain tumor in adults, has poor prognosis irrespective of therapeutic advances due to its radio-resistance and infiltrative growth into brain tissue. The present study assessed functions and putative druggability of protein breast cancer type 1 susceptibility protein (BRCA1)-associated Ataxia telangiectasia mutated (ATM)-activator 1 (BRAT1) as a crucial factor driving key aspects of GBM, including enhanced DNA damage response and tumor migration. By a stable depletion of BRAT1 in GBM and glioma stem-like (GSC) cell lines, we observed a delay in DNA double-strand break repair and increased sensitivity to radiation treatment, corroborated by in vitro and in vivo studies demonstrating impaired tumor growth and invasion. Proteomic analyses further emphasize the role of BRAT1’s cell migration and invasion capacity, with a notable proportion of downregulated proteins associated with these processes. In line with the genetic manipulation, we found that treatment with the BRAT1 inhibitor Curcusone D (CurD) significantly reduced GSC migration and invasion in an ex vivo slice culture model, particularly when combined with irradiation, resulting a synergistic inhibition of tumor growth and infiltration. Our results reveal that BRAT1 contributes to GBM growth and invasion and suggest that therapeutic inhibition of BRAT1 with CurD or similar compounds might constitute a novel approach for anti-GBM directed treatments.
- Open Access
- 8 November 2023
- Published by Springer Nature in EMBO Reports
- Vol. 24 (12) , e56964
Combining organotypic tissue culture with light‐sheet microscopy (OTCxLSFM) to study glioma invasion
Glioblastoma is a very aggressive tumor and represents the most common primary brain malignancy. Key characteristics include its high resistance against conventional treatments, such as radio- and chemotherapy and its diffuse tissue infiltration, preventing complete surgical resection. The analysis of migration and invasion processes in a physiological microenvironment allows for enhanced understanding of these phenomena and can lead to improved therapeutic approaches. Here, we combine two state-of-the-art techniques, adult organotypic brain tissue slice culture (OTC) and light-sheet fluorescence microscopy (LSFM) of cleared tissues in a combined method termed OTCxLSFM. Using this methodology, we can show that glioblastoma tissue infiltration can be effectively blocked through treatment with arsenic trioxide or WP1066, as well as genetic depletion of the tetraspanin, transmembrane receptor CD9, or signal transducer and activator of transcription 3 (STAT3). With our analysis pipeline, we gain single-cell level, three-dimensional information, as well as insights into the morphological appearance of the tumor cells.
- 8 November 2023
- Published by Springer Nature in EMBO Reports
- Vol. 24 (12) , e56964
Open AccessCombining organotypic tissue culture with light‐sheet microscopy (OTCxLSFM) to study glioma invasion
Glioblastoma is a very aggressive tumor and represents the most common primary brain malignancy. Key characteristics include its high resistance against conventional treatments, such as radio- and chemotherapy and its diffuse tissue infiltration, preventing complete surgical resection. The analysis of migration and invasion processes in a physiological microenvironment allows for enhanced understanding of these phenomena and can lead to improved therapeutic approaches. Here, we combine two state-of-the-art techniques, adult organotypic brain tissue slice culture (OTC) and light-sheet fluorescence microscopy (LSFM) of cleared tissues in a combined method termed OTCxLSFM. Using this methodology, we can show that glioblastoma tissue infiltration can be effectively blocked through treatment with arsenic trioxide or WP1066, as well as genetic depletion of the tetraspanin, transmembrane receptor CD9, or signal transducer and activator of transcription 3 (STAT3). With our analysis pipeline, we gain single-cell level, three-dimensional information, as well as insights into the morphological appearance of the tumor cells.